



PROGRAMME

FRIDAY 25 September

10.00	Registration, refreshments, exhibition and poster viewing
11.00	Welcome & uro-oncology round up: Amit Bahl, Chair, BUG
11.05	Prostate: <i>Joe O'Sullivan, Academic Clinical Oncologist, Queen's University Belfast</i>
11.25	Bladder: <i>Alison Birtle, Consultant Oncologist, Rosemere Cancer Centre, Lancashire Teaching Hospitals</i>
11.45	Renal: <i>Speaker TBC</i>
12.00	Testicular: <i>Robert Huddart, Professor and Honorary Consultant in Urological Oncology, Institute of Cancer Research</i>
12.10	Penile: <i>Amit Bahl, Consultant Clinical Oncologist, University Hospitals Bristol</i>
12.20	Discussion
12.30	Lunch, exhibition and poster viewing
13.45-14.30	Main session – Prostate: Joe O'Sullivan, Academic Clinical Oncologist, Queen's University Belfast PSMA radioligand: <i>Amarnath Challapalli, Consultant Clinical Oncologist, Bristol Cancer Institute</i> PARPs: <i>Rob Jones, Professor and Honorary Consultant, University of Glasgow & The Beatson West of Scotland Cancer Centre</i> Results of the toxicity of the PIVOTALboost trial: <i>Isabel Syndikus, Consultant Clinical Oncologist, The Clatterbridge Cancer Centre NHS Foundation Trust</i>
14.30-15.30	Seminar sessions 1
1A	Bladder: Vishwanath Hanchale, Chair BAUS Section of Oncology, Liverpool University Hospitals NHS Foundation Trust Case based discussion: 1. Session 1: NMIBC 1. High-Risk NMIBC – BCG or Early Cystectomy? 2. BCG-Unresponsive NMIBC – When Is It Time to Change Strategy? 2. Session 2: Rare Histological Subtypes 1. Micropapillary Bladder Cancer – Is Early Radical Treatment Justified? 2. Small Cell Carcinoma of the Bladder – A Different Disease, A Different Pathway 3. Session 3: Recently Approved NICE-Appraised Therapies 1. Peri-Operative Immunotherapy in MIBC – Selecting Patients for Durvalumab-Based Treatment 2. Advanced Urothelial Cancer – Integrating Enfortumab Vedotin, Pembrolizumab and Erdafitinib into Clinical Practice
1B	Prostate: Prantik Das, Consultant Clinical Oncologist, University Hospitals of Derby and Burton NHS Foundation Trust Practice enhancing – practical aspect of clinical practice, complex cases SABR Reirradiation: <i>Suneil Jain, Consultant Clinical Oncologist, Queen's University, Belfast</i> <i>Ann Henry, Professor in Clinical Oncology, Leeds Teaching Hospitals NHS Trust</i>



BUG

British Uro-oncology Group

Annual Meeting Brighton Metropole

25 - 26 September 2026

1C	Renal: Balaji Venugopal, Consultant in Medical Oncology, The Beatson West of Scotland Cancer Centre, Glasgow Case based discussion Speakers TBC
15.30	Refreshments, exhibition and poster viewing
16.15-17.00	Main session - Optimal systemic treatment of locally advanced bladder cancer: Yee Pei Song, Consultant Clinical Oncologist, The Christie NHS Foundation Trust, Manchester Neo-adjuvant and adjuvant systemic treatments: Sally Appleyard, Consultant Clinical Oncologist, University Hospitals Sussex The practical role of ctDNA: Andrew Hudson, Consultant Clinical Oncologist, The Christie NHS Foundation Trust, Manchester Definitive treatment for localised muscle invasive bladder cancer: Mohini Varughese, Consultant Clinical Oncologist, Royal Devon University Hospitals NHS Foundation Trust
17.00-17.30	Why should you look at my poster?: Mark Beresford, Consultant Clinical Oncologist, Royal United Hospital, Bath One minute presentations from each poster author
17.30-18.15	Welcome reception, exhibition and poster viewing
19.30	Predinner drinks
20.00	Conference dinner

SATURDAY 26 September

08.15	Registration, refreshments, exhibition and poster viewing
08.45-09.15	BUG Annual General Meeting
09.15-10.00	Main session – Systemic management of localised renal cancer: Rhona McMenemin, Consultant Clinical Oncologist, Aberdeen Royal Infirmary Neoadjuvant/adjuvant data: Giuseppe Bana, Consultant Medical Oncologist, Portsmouth Hospitals University NHS Trust Non clear cell: Speaker TBC SABR: Vincent Khoo, Consultant Clinical Oncologist, The Royal Marsden NHS Foundation Trust
10.00-11.00	Seminar sessions 2
2A	Prostate – Survivorship in prostate cancer: Hilary Glen, Consultant Medical Oncologist, The Beatson West of Scotland Cancer Centre, Glasgow Managing/optimising cardiovascular health for men on ADT: Tharshini Ramalingam, Cardio-oncologist, The Royal Brompton Hospital, London Bone health: Carolina Navarro Rodriguez, Clinical Oncology SpR, The Newcastle Upon Tyne Hospitals NHS Foundation Trust



BUG

British Uro-oncology Group

Annual Meeting Brighton Metropole

25 - 26 September 2026

2B	Medico-legal: Rob Jones, Professor and Honorary Consultant, University of Glasgow & The Beatson West of Scotland Cancer Centre <i>Jeremy Roussak, Barrister, Kings Chambers, Manchester</i> <i>Joe O'Sullivan, Academic Clinical Oncologist, Queen's University Belfast</i>
2C	AI - Role of AI in urological cancers: Alexander Vickers, Clinical SpR, Honorary Research Fellow & BUG Clinical Oncology Trainee Representative, The Christie NHS Foundation Trust & The University of Manchester & Shybi Mohamedkhan, ST4 Medical Oncology SpR and BUG Medical Oncology Trainee Representative, Royal Surrey County Hospital AI in uro-oncology pathology: <i>Jonathan Griffin, NIHR Clinical Lecturer in Histopathology, The University of Sheffield</i> AI and biobanking in uro-oncology: <i>Abhishek Mahajan, Consultant Radiologist, The Clatterbridge Cancer Centre NHS Foundation Trust</i> PROSECCA project: <i>Dr Archie MacNair, Radiation Oncologist, Edinburgh Cancer Centre</i>
11.00	Refreshments, exhibition and poster viewing
11.45-12.30	Helen Patterson Award for Registrar Research
11.45	Chair's welcome
11.50	2026 Winner's presentation: <i>Alexander Vickers, Clinical SpR & Honorary Research Fellow, The Christie NHS Foundation Trust & The University of Manchester</i>
11.55	Registrar presentations introduction
12.00	Paper 1- tbc
12.10	Paper 2- tbc
12.20	Paper 3- tbc
12.30-13.15	Main session: Amit Bahl, Chair, BUG NPCA – <i>Noel Clarke, Professor of Urological Oncology, The Christie NHS Foundation Trust</i> NKCA updates – <i>Jan Vander-Meulen, Senior Clinical Epidemiologist, London School of Hygiene and Tropical Medicine</i> NHS cancer plan and relevance - <i>Stephen Harden, President, The Royal College of Radiologists</i>
13.15-13.30	Closing session: Amit Bahl, Chair, BUG Prize giving Helen Patterson Award for registrar research Best poster prize
13.30-14.30	Lunch and depart

BUG would like to thank the following organisations for their support of the 2026 Annual Meeting

KEY SPONSORS



SUPPORTING SPONSORS



BUG recognises the ABPI Code of Practice and the implications for pharmaceutical companies that support the Annual meeting by way of sponsoring and exhibiting. Industry partners have no input into the educational content of the programme